Abbott (ABT) EV/EBITDA Multiple

Graphic logo of Abbott Laboratories Inc. (ABT)

The current EV/EBITDA ratio of Abbott Laboratories (ABT), based on partnerships with government entities and IT developers, demonstrates the dynamics of assets relative to operating income, where 20.25 determines the current value of the metric. Growth is driven by the expansion of FreeStyle Libre and market diversification. Meanwhile, the decline in revenue from COVID tests has been successfully offset by the development of medical devices, despite moderate regulatory risks.

ABT (Abbott Laboratories Inc.) Business Value to Operating Income Before Depreciation history from 11/23/2025 to 11/10/2026

ABT (abbott.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Abbott Laboratories Inc.|ABT - Analyst Median Target
- market capitalization details:
Market Capitalization Abbott Corp.|ABT - Real Price to Acquire Entire Company
- issuer book value statistics:
Accounting Value per Share Abbott|ABT - Accounting Value of Company|Market Value to Book Value Ratio abbott.com|ABT - Cumulative Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Abbott Laboratories|ABT - Long-Term Liabilities to Capital|Short-Term Debt to Capital Abbott|ABT - Company Aggregate Debt|Debts to Book Capitalization Abbott Corp.|ABT - Long-Term Debt Volume|Company Short-Term Debts Abbott|Quick Ratio abbott.com
- net income and valuation multiples indicators:
ABT - Net Profit|Expected Profit Abbott Laboratories|ABT - Price to Earnings Ratio|Projected Price to Earnings Abbott Laboratories|ABT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Abbott Corp.|ABT - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Abbott|ABT - Net earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months abbott.com|ABT - Earnings growth in current year|Earnings growth forecast for next year Abbott Laboratories
Fundamental company valuation:Abbott Laboratories Inc. ABT
Product sample of abbott.com

Investors must distinguish fundamental capital stability from short-term market noise. The EV/EBITDA metric compares the total enterprise value, including debt, with operating profit before taxes and amortization, revealing the actual overvaluation of an asset. By analyzing fluctuations in the EV/EBITDA level of a company, one can determine an entry point without the risk of buying at the peak. The diversified portfolio of Abbott Laboratories (ABT) and the holding's excess liquidity make this indicator a highly reliable valuation tool.

Analysis of competing companies

EV/EBITDA Multiple TMO (Thermo Fisher Corp)|Total Company Value to Operating Income Before Depreciation Ratio GE HealthCare Inc. (GEHC)|Mettler-Toledo International - EV/EBITDA Multiple|waters.com (WAT) - Enterprise Value to EBITDA Ratio|TECH (Bio-Techne) - Enterprise Value to EBITDA Ratio|Bruker Corp - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Azenta Life Sciences|Enterprise Value to EBITDA Ratio Varex Imaging Corp. (VREX)|EV/EBITDA Multiple SMLR|BFLY - Company Value to EBITDA|EV/EBITDA Multiple MLAB (Mesa Labs)|QSI: Enterprise Value to Operating Income Before Depreciation|Nanox - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Quanterix Inc QTRX|MASS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CapsoVision|MXCT (MaxCyte) - EV/EBITDA Multiple|EV/EBITDA Multiple Rapid Micro|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Seer Inc. (SEER)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HYPR (Hyperfine Medical)|FONAR Corporation - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation DXR|Spectral AI, Inc. - EV/EBITDA Multiple|Company Value to EBITDA Organovo Holdings|Aclarion Corp (ACON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Multiple Akoya Biosciences, Inc. AKYA|Enterprise Value to EBITDA Ratio THMO|EV/EBITDA Multiple Talis Biomedical Corp|EV/EBITDA Multiple TTOO